Cargando…

Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study

Despite some variability in ideal serum Adalimumab (ADA) concentrations, there is increasing evidence that higher concentrations of anti-TNF-α agents can be associated with sustained efficacy, and low or undetectable levels may lead to loss of response. This study aims to correlate serum ADA concent...

Descripción completa

Detalles Bibliográficos
Autores principales: de Souza, Letícia Rodrigues, Magro, Daniela Oliveira, Teixeira, Fábio Vieira, Parra, Rogério Serafim, Miranda, Eron Fábio, Féres, Omar, Saad-Hossne, Rogério, Soares Prates Herrerias, Giedre, Nisihara, Renato Mitsunori, Coy, Claudio Saddy Rodrigues, Sassaki, Ligia Yukie, Kotze, Paulo Gustavo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967155/
https://www.ncbi.nlm.nih.gov/pubmed/36839908
http://dx.doi.org/10.3390/pharmaceutics15020586
_version_ 1784897194647617536
author de Souza, Letícia Rodrigues
Magro, Daniela Oliveira
Teixeira, Fábio Vieira
Parra, Rogério Serafim
Miranda, Eron Fábio
Féres, Omar
Saad-Hossne, Rogério
Soares Prates Herrerias, Giedre
Nisihara, Renato Mitsunori
Coy, Claudio Saddy Rodrigues
Sassaki, Ligia Yukie
Kotze, Paulo Gustavo
author_facet de Souza, Letícia Rodrigues
Magro, Daniela Oliveira
Teixeira, Fábio Vieira
Parra, Rogério Serafim
Miranda, Eron Fábio
Féres, Omar
Saad-Hossne, Rogério
Soares Prates Herrerias, Giedre
Nisihara, Renato Mitsunori
Coy, Claudio Saddy Rodrigues
Sassaki, Ligia Yukie
Kotze, Paulo Gustavo
author_sort de Souza, Letícia Rodrigues
collection PubMed
description Despite some variability in ideal serum Adalimumab (ADA) concentrations, there is increasing evidence that higher concentrations of anti-TNF-α agents can be associated with sustained efficacy, and low or undetectable levels may lead to loss of response. This study aims to correlate serum ADA concentrations with clinical and endoscopic activity in patients with Crohn’s disease (CD). A cross-sectional and multicentric study was performed with patients with CD, who used ADA for at least 24 weeks. Patients were allocated into groups according to the presence of clinical or endoscopic disease activity. Serum ADA concentrations were measured and compared between groups. Overall, 89 patients were included. A total of 27 patients had clinically active CD and 62 were in clinical remission. Forty patients had endoscopic disease activity and 49 were in endoscopic remission. The mean serum ADA concentration was 10.2 μg/mL in patients with clinically active CD and 14.3 μg/mL in patients in clinical remission (p = 0.395). The mean serum ADA concentration in patients with endoscopic activity was 11.3 μg/mL as compared to 14.5 μg/mL in those with endoscopic remission (p = 0.566). There was no difference between serum ADA concentrations regarding clinical or endoscopic activity in CD, as compared to patients in remission
format Online
Article
Text
id pubmed-9967155
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99671552023-02-26 Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study de Souza, Letícia Rodrigues Magro, Daniela Oliveira Teixeira, Fábio Vieira Parra, Rogério Serafim Miranda, Eron Fábio Féres, Omar Saad-Hossne, Rogério Soares Prates Herrerias, Giedre Nisihara, Renato Mitsunori Coy, Claudio Saddy Rodrigues Sassaki, Ligia Yukie Kotze, Paulo Gustavo Pharmaceutics Article Despite some variability in ideal serum Adalimumab (ADA) concentrations, there is increasing evidence that higher concentrations of anti-TNF-α agents can be associated with sustained efficacy, and low or undetectable levels may lead to loss of response. This study aims to correlate serum ADA concentrations with clinical and endoscopic activity in patients with Crohn’s disease (CD). A cross-sectional and multicentric study was performed with patients with CD, who used ADA for at least 24 weeks. Patients were allocated into groups according to the presence of clinical or endoscopic disease activity. Serum ADA concentrations were measured and compared between groups. Overall, 89 patients were included. A total of 27 patients had clinically active CD and 62 were in clinical remission. Forty patients had endoscopic disease activity and 49 were in endoscopic remission. The mean serum ADA concentration was 10.2 μg/mL in patients with clinically active CD and 14.3 μg/mL in patients in clinical remission (p = 0.395). The mean serum ADA concentration in patients with endoscopic activity was 11.3 μg/mL as compared to 14.5 μg/mL in those with endoscopic remission (p = 0.566). There was no difference between serum ADA concentrations regarding clinical or endoscopic activity in CD, as compared to patients in remission MDPI 2023-02-09 /pmc/articles/PMC9967155/ /pubmed/36839908 http://dx.doi.org/10.3390/pharmaceutics15020586 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
de Souza, Letícia Rodrigues
Magro, Daniela Oliveira
Teixeira, Fábio Vieira
Parra, Rogério Serafim
Miranda, Eron Fábio
Féres, Omar
Saad-Hossne, Rogério
Soares Prates Herrerias, Giedre
Nisihara, Renato Mitsunori
Coy, Claudio Saddy Rodrigues
Sassaki, Ligia Yukie
Kotze, Paulo Gustavo
Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study
title Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study
title_full Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study
title_fullStr Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study
title_full_unstemmed Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study
title_short Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study
title_sort adalimumab serum concentrations, clinical and endoscopic disease activity in crohn’s disease: a cross-sectional multicentric latin american study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967155/
https://www.ncbi.nlm.nih.gov/pubmed/36839908
http://dx.doi.org/10.3390/pharmaceutics15020586
work_keys_str_mv AT desouzaleticiarodrigues adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy
AT magrodanielaoliveira adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy
AT teixeirafabiovieira adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy
AT parrarogerioserafim adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy
AT mirandaeronfabio adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy
AT feresomar adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy
AT saadhossnerogerio adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy
AT soarespratesherreriasgiedre adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy
AT nisihararenatomitsunori adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy
AT coyclaudiosaddyrodrigues adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy
AT sassakiligiayukie adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy
AT kotzepaulogustavo adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy